Head to head
Elanco Animal Health vs Takeda Pharmaceutical
Side-by-side on the measures that matter, with a plain-English read. Full detail: ELAN · TAK
ELAN
Elanco Animal Health
22.36-0.53%
1-year price shape — +9% over the period
Quant Rating D · 49/100
vs
TAK
Takeda Pharmaceutical
18.37+1.49%
1-year price shape — +29% over the period
Quant Rating C · 70/100
1-year performance, rebased to 100
Takeda Pharmaceutical edges it on the scoreable measures. Takeda Pharmaceutical has the highest Quant Rating (70); Takeda Pharmaceutical has done best over the past year (+29%); Takeda Pharmaceutical pays the highest dividend yield.
| ELAN | TAK | |
|---|---|---|
| Snapshot | ||
| Sector | Drug Manufacturers - Specialty & Generic | -- |
| Last price | 22.36 | 18.37 |
| Change today | -0.53% | +1.49% |
| 1-year return | +9.3% | +29.2% |
| Market cap | $11.17B | $58.68B |
| 52-week range | 19.40 – 27.98 | 12.77 – 19.10 |
| Valuation | ||
| P/E (TTM) | -54.54 | -55.67 |
| P/E percentile, own 5-yr range | 11th | 4th |
| P/B | 1.70 | 1.23 |
| Dividend yield | 0.00% | 3.26% |
| Profitability & growth | ||
| EPS (TTM) | -0.47 | -0.31 |
| Net profit (TTM) | $-234.82M | $-977.54M |
| Revenue (TTM) | $5.02B | $4.62T |
| Revenue growth (YoY) | +10.2% | +10.2% |
| Gross margin | 55.4% | 65.5% |
| Operating margin | 6.6% | 10.4% |
| Net margin | -4.0% | -3.5% |
| Free cash flow (TTM) | $379.00M | $626.68B |
| Ownership & sentiment | ||
| Institutional ownership | 114.2% | 51.5% |
| Insider activity (12mo) | 49 buy / 1 sell | 22 buy / 28 sell |
| Short interest (% of float) | 6.4% | 0.1% |
| Analyst consensus | 92% buy / 8% hold (12) | 100% buy (1) |
| Analyst price target | $31 (+41%) | $43 (+134%) |
| StockVane view | ||
| StockVane Quant Rating | D (49) | C (70) |
| Company | ||
| Employees | 9,400 | 47,029 |
| Founded | 1954 | 1781 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.